Original document(4 pages)  中文版
    The medicine for auxiliary treatment after radiotherapy and chemothaphy of tumor is Chinese medicine preparation prepared with glossy ganoderma, astragalus root, roxburgh ross fruit, prepared rhizome of rehmannia, privet fruit, epimedium and pinellia tuber as main material and through conventional pharmaceutical process. The present invention is developed based on Miao medical theory and is prepared with common Chinese herbal medicine material. The medicine has the functions of benefiting vital energy, clearing away toxic matter, dissipating mass, eliminating swelling, regulating stomach energy and tranquilizing. It is used for auxiliary treatment of weakness, asthenia, poor appetite, vomit, insomnia, etc. due to leucopenia, thrombocytopenia and hypoimmuity after radiotherapy and chemotherapy of tumor.
Application Number
申请号
03117385 Application Date
申请日
2003.02.28
Title 名称 Medicine for auxiliary trearment after radiotherapy and chemotherapy of tumor
Publication Number
公开号
1440795 Publication Date
公开日
2003.09.10
Approval Pub. Date Granted Pub. Date
International Classification 分类号 A61K35/78,A61P35/00
Applicant(s) Name
申请人
Hanfang Pharmaceutical Co., Ltd., Guizhou
Address 地址 550001
Inventor(s) Name 发明人 Deng Jie, Long Xianfeng
Attorney & Agent 代理人 li dagang
More information 更  多  信  息


 Related patents information
Medicine for clearing away heat, purging fire-evil, calming nerves and relaxing bowels
Medicine for clearing away heat and toxic matter, promoting diuresis and stopping itching
Medicine for stopping pain and strengthening bone
Discrimination of hydrolysate in aconite injection
Photochromism reversible tautomerization processing method for photochromic glass
Metathetical process for preparing potassium sulfate by step-by-step crystallizations and separations
Gravity separation method for producing potassium sulfate
Ladder easy to carry about
Local vibration source for RF phase lock
Multifunctional converter
Google
Note:All patent data come from State Intellectual Property Office of the People's Republic of China. If there were discrepancies between here and the State Intellectual Property office, the later is more accurate. The patent data is only for public exchange and learning purposes. We are not responsible for the adverse consequences with unverified use of the data.